Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery.
Thompson J T, Smiddy W E, Williams G A, Sjaarda R N, Flynn H W, Margherio R R et al.
This study found recombinant TGF-beta2 offered no significant benefit over placebo for macular hole closure or visual acuity improvement, suggesting it's not a useful surgical adjunct.